Quest will use the proceeds to repurchase approximately $300m of its shares as part of the stock buyback program.
The divestment of the non-core business assets will allow Quest to focus on its diagnostic information services business.
The Swedish diagnostic company HemoCue develops, produces and markets hemoglobin, glucose and other point-of-care testing systems, while Radiometer provides technologically advanced acute care solutions that simplify and automate all phases of acute care testing.
